| Medical diagnostics duo |
| Tuesday, March 03, 2009 |
|
"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women’s health. "The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers. "In the company’s latest reported first quarter, sales increased approximately 53% to $73.6 million from $48.3 million in the first quarter of last year. "Myriad Genetics reported earnings per share of $0.30 in the latest reported first quarter versus a loss in the same quarter of last year. "Note that revenues in the latest reported June quarter included a one-time licensing payment of $100 million which makes the year over year growth comparison appear slower than it otherwise would. Clients of Oberweis Asset Management own approximately 1,500 shares. "Thoratec is a leader in therapies to address advanced heart failure (HF) and point-of-care diagnostics. For advanced HF, Thoratec develops, manufactures and markets proprietary medical devices used for mechanical circulatory support. "The company’s primary product lines are its ventricular assist devices (VAD), including the new HeartMate II product, which received FDA approval in April 2008. The product is also CE Mark approved in Europe. VAD’s are clinically proven to improve patient survival and quality of life. "In the company’s latest reported third quarter, sales increased approximately 44% to $80.8 million from $56.1 million in the third quarter of last year. "Thoratec reported earnings per share of $0.17 in the latest reported third quarter versus $0.04 in the same quarter of last year. Clients of Oberweis Asset Management own approximately 184,000 shares." |
Sign up now for our free Daily Newsletter
| Meet the KCI editors |
Join Roger Conrad, Gregg Early, Elliott Gue, and Yiannis Mostrous in San Diego on April 23-24. Call 1-800-832-2330 or go to www.InvestingSummit.com. |
| Dividend Still Don't Lie |
Dividends Don't Lie -- by IQ Trends founder Geraldine Weiss -- is one of the all-time great investment books. Now, editor Kelley Wright is following up this classic with Dividend Still Don't Lie, which can be ordered at a significant discount. |
| Keith Fitz-Gerald: Fiscal Hangover |
Get a $10 discount on Keith's new book on global investing -- Fiscal Hangover. Click here. |
| Red, White & Bold |
Global expert Carl Delfeld's new book -- Red, White & Bold -- is now available. |
| Gone Fishin' Portfolio |
The Oxford Club's Alexander Green has released an exceptional new book-- The Gone Fishin' Portfolio -- which provides an all-weather approach to investing. |
| EconoPower |
Mark Skousen's latest book, “EconoPower: How a New Generation of Economists is Transforming the World” (Wiley & Sons), is available for $16.47 (plus shipping) from Amazon.com (retail $24.95). |
| Guide to seasonal trading |
Sy Harding has published Beat the Market the Easy Way -- an in-depth review of seasonal market patterns and their application to long-term timing. |
| Dick Davis Dividend |
In The Dick Davis Dividend, the investing legend shares a lifetime of insights on investing. |